Business Context and Reporting Period
Company: Bruker Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2010
Business Overview: Bruker designs and manufactures proprietary life science and materials research systems, including X-ray, magnetic resonance, mass spectrometry, and optical emission spectroscopy technologies. The company operates in two reportable segments: Scientific Instruments and Energy & Supercon Technologies. The company also manufactures superconducting materials and field analytical systems for CBRNE detection.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Total Revenue | $310.2 | $888.8 |
| Gross Profit | $146.9 | $408.9 |
| Gross Margin | 47.4% | 46.0% |
| Operating Income | $39.3 | $104.1 |
| Operating Margin | 12.7% | 11.7% |
| Net Income (Attributable to Bruker) | $27.4 | $66.1 |
| Diluted EPS | $0.17 | $0.40 |
| Cash and Cash Equivalents | $188.0 | $188.0 (Balance Sheet) |
| Net Cash Provided by Operating Activities | N/A | $62.7 |
| Total Debt (Long-term + Current) | $121.4 | $121.4 (Balance Sheet) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17.0% ($45.1M) for the quarter and 18.8% ($140.7M) for the nine months compared to 2009. Organic growth was driven by increased demand in magnetic resonance, mass spectrometry, and X-ray technologies, as well as higher demand for superconducting wire.
- Acquisitions: Revenue growth included approximately $17.1M from the acquisition of the chemical analysis business (Varian/Agilent) in the quarter and $27.6M from acquisitions in the nine-month period.
- Foreign Exchange Impact: A strengthening U.S. Dollar negatively impacted reported revenue by approximately $18.1M in the quarter and $5.3M in the nine-month period.
- Margin Expansion: Gross margins improved to 47.4% (Q3) and 46.0% (YTD) from 45.0% and 44.5% in the prior year periods, respectively. This was driven by a favorable product mix (higher-end instrumentation) and the weakening Euro relative to production costs.
- Operating Expenses: Selling, general, and administrative (SG&A) and R&D expenses increased in absolute dollars but decreased as a percentage of revenue due to operating leverage.
Guidance, Outlook, Risks, and Unusual Items
- Acquisitions: On October 7, 2010 (post-period), the company completed the acquisition of Veeco Metrology Inc. (nano surfaces business) for $229.4M, financed by $167.6M in new debt and cash on hand. On October 1, 2010, the company borrowed $170.0M under its revolving credit facility to finance this acquisition.
- Strategic Initiatives: The company plans to sell a minority ownership position in its Bruker Energy & Supercon Technologies (BEST) subsidiary via an IPO to improve visibility and access to financing.
- Tax Credits: In Q3 2010, the company identified additional U.S. Federal R&D tax credits of approximately $2.8M, reducing the effective tax rate by 7.3% for the quarter.
- Legal Contingencies: The company recorded an accrual for an expected loss from a patent infringement action brought by The Research Foundation of the State University of New York (SUNY). A settlement in principle was reached in October 2010.
- Working Capital: Cash flow from operations was lower than net income due to a significant increase in inventory ($55.5M outflow) to support anticipated fourth-quarter revenues.
- Risks: Risks include the potential failure of the BEST IPO, foreign exchange volatility, and the impact of government spending cuts in key European markets.
Investor Verification Checklist
- Debt Capacity: Verify the impact of the $170M borrowing on October 1, 2010, on the company's leverage ratios and compliance with credit agreement covenants.
- Inventory Levels: Monitor the $487.8M inventory balance and the company's ability to convert this into revenue in Q4 to avoid future write-downs.
- Acquisition Integration: Assess the integration progress and revenue contribution of the Veeco Metrology and Varian chemical analysis acquisitions.
- Legal Settlement: Confirm the final terms and financial impact of the SUNY patent infringement settlement.
- BEST IPO Status: Track the progress of the proposed IPO for the Energy & Supercon Technologies subsidiary.